Champions Oncology (CSBR) Reports Q2 EPS of $0.03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Champions Oncology Reports Quarterly Revenue of $7.6 Million
December 16, 2019 4:01 PM ESTRecords Second Quarter Income of $291,000
HACKENSACK, NJ / ACCESSWIRE / December 16, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the second fiscal quarter ended October 31, 2019.
Second Quarter and Recent Business Highlights:
Quarterly revenue of $7.6 million, an increase of 14% year-over-yearReported income of $546,000, excluding stock-based compensation and depreciationAchieved record quarterly bookingsFormed strategic partnership to expand our ex-vivo platform and... More